Skip to main navigation
Skip to main content
Denali Therapeutics
  • Home
  • Scientific Approach
    • GENETIC PATHWAY POTENTIAL
    • ENGINEERING BRAIN DELIVERY
    • BIOMARKER-DRIVEN DEVELOPMENT
    • PUBLICATIONS
  • Pipeline
  • Patients
  • Investor & Media Relations
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
  • Leadership
  • Partnering
  • Careers
    • Job Openings
    • STEM Outreach Overview
    • Student Internships
    • Postdoc Program
  • Contact

SEC Filings

Sign Up For Updates
Filing date Form Description View
Aug 14, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000176.pdf
0001714899-25-000176.rtf
0001714899-25-000176.xls
Aug 14, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001724311-25-000011.pdf
0001724311-25-000011.rtf
0001724311-25-000011.xls
Aug 13, 2025 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing View HTML
0001950047-25-005790.pdf
0001950047-25-005790.rtf
Aug 12, 2025 SCHEDULE 13G/A SCHEDULE 13G/A - Description View HTML
0000902219-25-000288.pdf
0000902219-25-000288.rtf
0000902219-25-000288.xls
Aug 12, 2025 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing View HTML
0001724311-25-000006.pdf
0001724311-25-000006.rtf
Aug 12, 2025 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing View HTML
0001714899-25-000172.pdf
0001714899-25-000172.rtf
Aug 11, 2025 8-K Report of unscheduled material events or corporate event View HTML
0001714899-25-000167.pdf
0001714899-25-000167.rtf
0001714899-25-000167.xls
Aug 11, 2025 10-Q Quarterly report which provides a continuing view of a company's financial position View HTML
0001714899-25-000170.pdf
0001714899-25-000170.rtf
0001714899-25-000170.xls
Aug 07, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000153.pdf
0001714899-25-000153.rtf
0001714899-25-000153.xls
Jul 11, 2025 4 Statement of changes in beneficial ownership of securities View HTML
0001714899-25-000149.pdf
0001714899-25-000149.rtf
0001714899-25-000149.xls
Pagination
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 719 results

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox


  • Investor & Media Relations

CONTACT US

161 Oyster Point Blvd- South San Francisco, CA 94080

© 2025 Denali Therapeutics

  • Privacy Policy
  • Terms of Use

©2025 Denali Therapeutics | 161 Oyster Point Boulevard, South San Francisco, CA 94080

  • Privacy Policy
  • Terms of Use